Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.

Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.

PMID:
30181174
2.

Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.

Cavenagh JD, Popat R.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):501-507. doi: 10.1016/j.clml.2018.05.007. Epub 2018 May 24. Review.

PMID:
29804873
3.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH.

J Clin Oncol. 2018 May 20;36(15):1486-1497. doi: 10.1200/JCO.2017.76.3425. Epub 2018 Mar 30.

4.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

5.

Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.

Davies JK, Hassan S, Sarker SJ, Besley C, Oakervee H, Smith M, Taussig D, Gribben JG, Cavenagh JD.

Br J Haematol. 2018 Feb;180(3):346-355. doi: 10.1111/bjh.14980. Epub 2017 Oct 26.

PMID:
29076145
6.

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P.

Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1.

7.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.

Leukemia. 2017 Dec;31(12):2799-2806. doi: 10.1038/leu.2017.159. Epub 2017 May 26.

8.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK.

Blood. 2017 Mar 2;129(9):1143-1154. doi: 10.1182/blood-2016-07-730648. Epub 2016 Nov 21.

9.

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group.

Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.

10.

Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.

Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T.

J Med Econ. 2016;19(3):243-58. doi: 10.3111/13696998.2015.1115407. Epub 2015 Nov 17.

PMID:
26517601
11.

Toward a better management of older patients with acute myeloid leukemia.

Liapis K, Cavenagh JD.

Future Oncol. 2015;11(5):715-8. doi: 10.2217/fon.15.8. No abstract available.

12.

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Špička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF.

Am J Hematol. 2015 Jan;90(1):42-9. doi: 10.1002/ajh.23868.

13.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG.

Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25242045
14.

Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.

Rohatiner AZ, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R, Björkholm M, Johnson S, Newland AC, Cavenagh JD, Macdougall F, Waters R, Fitzgibbon J, Barbui T, Lister A.

Br J Haematol. 2014 Dec;167(5):724-6. doi: 10.1111/bjh.13055. Epub 2014 Jul 29. No abstract available.

PMID:
25074579
15.

Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.

Davies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, Gribben JG.

Br J Haematol. 2013 Aug;162(4):525-9. doi: 10.1111/bjh.12402. Epub 2013 May 29.

PMID:
23718277
16.

Mullins' syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra.

Longhurst HJ, Yong PF, Manson AL, Cavenagh JD, Grigoriadou S, Buckland MS.

QJM. 2015 Jun;108(6):497-501. doi: 10.1093/qjmed/hcs208. Epub 2012 Oct 29. No abstract available.

17.

T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.

Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, Agrawal S, Cavenagh JD, Lister TA, Gribben JG.

Br J Haematol. 2012 Jun;157(5):580-5. doi: 10.1111/j.1365-2141.2012.09106.x. Epub 2012 Mar 26.

PMID:
22449197
18.

Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract.

Joshi NM, Hassan S, Jasani P, Dixon S, Cavenagh JD, Oakervee HE, Smith M, Agrawal SA, Auer R, de Vos J, Langmead L, Rampton DS, Gribben JG, Taussig DC.

Br J Haematol. 2012 May;157(3):403-7. doi: 10.1111/j.1365-2141.2011.09014.x. Epub 2012 Jan 9. No abstract available.

PMID:
22225419
19.

Differential and tumor-specific expression of CD160 in B-cell malignancies.

Farren TW, Giustiniani J, Liu FT, Tsitsikas DA, Macey MG, Cavenagh JD, Oakervee HE, Taussig D, Newland AC, Calaminici M, Bensussan A, Jenner M, Gribben JG, Agrawal SG.

Blood. 2011 Aug 25;118(8):2174-83. doi: 10.1182/blood-2011-02-334326. Epub 2011 Jun 28.

20.

Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.

Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM.

Br J Haematol. 2009 Sep;146(5):574-6. doi: 10.1111/j.1365-2141.2009.07763.x. Epub 2009 Jun 15. No abstract available.

PMID:
19538531
21.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J.

Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

PMID:
19170677
22.

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.

Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J, Cavenagh JD, Craddock C, Orchard KH, Olavarria E, McQuaker G, Collin M, Marks DI; British Society of Blood and Marrow Transplantation.

Bone Marrow Transplant. 2009 May;43(9):709-15. doi: 10.1038/bmt.2008.375. Epub 2008 Nov 24.

PMID:
19029965
23.

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH.

Bone Marrow Transplant. 2008 Dec;42(12):783-9. doi: 10.1038/bmt.2008.255. Epub 2008 Aug 25.

PMID:
18724393
24.

Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia.

Raghavan M, Smith LL, Lillington DM, Chaplin T, Kakkas I, Molloy G, Chelala C, Cazier JB, Cavenagh JD, Fitzgibbon J, Lister TA, Young BD.

Blood. 2008 Aug 1;112(3):814-21. doi: 10.1182/blood-2008-01-132431. Epub 2008 May 19.

25.

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.

Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, Esseltine DL, Drake M, Morris C, Cavenagh JD.

Br J Haematol. 2008 May;141(4):512-6. doi: 10.1111/j.1365-2141.2008.06997.x. Epub 2008 Mar 26.

PMID:
18371113
26.

Survey of bereavement support provided by Australian palliative care services.

Mather MA, Good PD, Cavenagh JD, Ravenscroft PJ.

Med J Aust. 2008 Feb 18;188(4):228-30.

PMID:
18279130
27.

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC.

Leukemia. 2008 Apr;22(4):842-9. doi: 10.1038/sj.leu.2405087. Epub 2008 Jan 17.

PMID:
18200040
28.

Position statement on the use of bortezomib in multiple myeloma.

Morgan GJ, Davies FE, Cavenagh JD, Jackson GH; United Kingdom Myeloma Forum (UKMF); Haematology Oncology Task Force of the British Committee for Standards in Haematology.

Int J Lab Hematol. 2008 Feb;30(1):1-10. doi: 10.1111/j.1751-553X.2007.01020.x. Review.

PMID:
18190461
29.

The risk of antimalarials in patients with renal failure.

Thorogood N, Atwal S, Mills W, Jenner M, Lewis DA, Cavenagh JD, Agrawal SG.

Postgrad Med J. 2007 Dec;83(986):e8.

30.

Development of original donor cell leukemia after successful engraftment from a second donor.

Stevens JM, Syndercombe-Court D, Oakervee HE, McCloskey D, Jenner MJ, Gribben JG, Cavenagh JD.

Blood. 2007 Dec 15;110(13):4621-2. No abstract available.

32.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.

Br J Haematol. 2007 Jun;137(5):429-35. Epub 2007 Apr 19.

PMID:
17451408
33.
34.

A complication of steroid therapy in acute leukaemia--a case report.

Quint J, Mills W, Lewis D, Cavenagh JD, Agrawal SG.

Hematology. 2006 Apr;11(2):97-9.

PMID:
16753848
35.

Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease.

Davies JK, Taussig DC, Oakervee H, Davies AJ, Agrawal SG, Gribben JG, Lister TA, Cavenagh JD.

J Clin Oncol. 2006 May 10;24(14):e23-5. No abstract available.

PMID:
16682729
36.

What are the essential medications in pallative care? - a survey of Australian palliative care doctors.

Good PD, Cavenagh JD, Currow DC, Woods DA, Tuffin PH, Ravenscroft PJ.

Aust Fam Physician. 2006 Apr;35(4):261-4.

37.

Low dose antithymocyte globulin for the treatment of older patients with aplastic anaemia.

Killick SB, Cavenagh JD, Davies JK, Marsh JC.

Leuk Res. 2006 Dec;30(12):1517-20. Epub 2006 Mar 10.

PMID:
16530266
38.

The importance of consistent use of denominators across patient groups in assessing responses in clinical trials.

Davies JK, Cavenagh JD.

Br J Haematol. 2006 Mar;132(6):794-5; author reply 795. No abstract available.

PMID:
16487183
39.

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.

Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NC, Cavenagh JD.

Leuk Res. 2006 Apr;30(4):373-8. Epub 2005 Sep 22.

PMID:
16183119
40.

Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia.

Kaya B, Davies CE, Oakervee HE, Silver NC, Gawler J, Cavenagh JD.

J Clin Pathol. 2005 Sep;58(9):994-5.

41.

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD.

Br J Haematol. 2005 Jun;129(6):755-62.

PMID:
15953001
42.

Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care.

Gordon AC, Oakervee HE, Kaya B, Thomas JM, Barnett MJ, Rohatiner AZ, Lister TA, Cavenagh JD, Hinds CJ.

Anaesthesia. 2005 Apr;60(4):340-7.

43.

Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.

Smith ML, Arch R, Smith LL, Bainton N, Neat M, Taylor C, Bonnet D, Cavenagh JD, Andrew Lister T, Fitzgibbon J.

Br J Haematol. 2005 Feb;128(3):318-23.

PMID:
15667533
44.

Mutation of CEBPA in familial acute myeloid leukemia.

Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J.

N Engl J Med. 2004 Dec 2;351(23):2403-7.

45.

Subacute immune response to primary EBV infection leading to post-transplant lymphoproliferative disease in a renal transplant patient.

Leaver S, Amlot P, Thuraisingham R, Norton A, Aitken C, Cavenagh JD.

Clin Lab Haematol. 2004 Oct;26(5):351-3.

PMID:
15485466
46.

Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology.

Pellagatti A, Esoof N, Watkins F, Langford CF, Vetrie D, Campbell LJ, Fidler C, Cavenagh JD, Eagleton H, Gordon P, Woodcock B, Pushkaran B, Kwan M, Wainscoat JS, Boultwood J.

Br J Haematol. 2004 Jun;125(5):576-83.

PMID:
15147372
47.

Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting.

Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, Amess JA, Rohatiner AZ, Lister TA, Barnett MJ.

J Clin Oncol. 2003 Aug 15;21(16):3060-5.

PMID:
12915594
48.

Autoimmune cytopenias in the 22q11.2 deletion syndrome.

Davies JK, Telfer P, Cavenagh JD, Foot N, Neat M.

Clin Lab Haematol. 2003 Jun;25(3):195-7.

PMID:
12755799
49.

A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia.

Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC.

Br J Haematol. 2003 Feb;120(4):679-84.

PMID:
12588356
50.

Thalidomide in multiple myeloma: current status and future prospects.

Cavenagh JD, Oakervee H; UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces.

Br J Haematol. 2003 Jan;120(1):18-26. No abstract available.

PMID:
12492572

Supplemental Content

Loading ...
Support Center